What is William Blair’s Forecast for NuCana Q1 Earnings?

NuCana plc (NASDAQ:NCNA) – Equities researchers at William Blair issued their Q1 2026 EPS estimates for NuCana in a research note issued on Thursday, March 20th. William Blair analyst M. Phipps forecasts that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for NuCana’s current full-year earnings is ($13.42) per share. William Blair also issued estimates for NuCana’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at ($0.01) EPS.

NuCana Price Performance

NASDAQ:NCNA opened at $0.79 on Monday. The company has a market capitalization of $2.09 million, a price-to-earnings ratio of -0.08 and a beta of 0.89. NuCana has a 1-year low of $0.69 and a 1-year high of $10.79. The business has a 50 day moving average of $0.96 and a 200 day moving average of $1.51.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $2.11.

Institutional Investors Weigh In On NuCana

A number of institutional investors have recently made changes to their positions in NCNA. Two Sigma Securities LLC purchased a new position in shares of NuCana during the 4th quarter valued at $25,000. Citadel Advisors LLC purchased a new stake in shares of NuCana in the fourth quarter valued at approximately $30,000. Virtu Financial LLC purchased a new stake in shares of NuCana in the 4th quarter worth approximately $48,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in NuCana in the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.